Cyteir Therapeutics (CYT) Stock Analysis

What Cyteir Therapeutics does

Cyteir Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to innovating and bringing to market cutting-edge precision oncology medicines. Its flagship compound, CYT-0851, is an novel, orally administered small molecule drug candidate, designed for once-daily dosing. This therapy is currently undergoing Phase I/II clinical evaluations, both as a standalone treatment and in combination with other drugs, targeting a broad range of solid tumors and hematologic malignancies. Furthermore, the company is advancing CYT-1853, another promising candidate in preclinical development for similar oncological indications. Cyteir Therapeutics was established in 2012 and is headquartered in Lexington, Massachusetts.

Key metrics

ETFs linked to CYT

Broad-market and Healthcare sector ETFs an investor holding Cyteir Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how CYT fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Cyteir Therapeutics?

Cyteir Therapeutics trades under the ticker CYT on NASDAQ.

Which exchange is CYT listed on?

CYT is listed on NASDAQ.

What sector does Cyteir Therapeutics operate in?

Cyteir Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze CYT in a portfolio?

PortView shows CYT's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.